Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
| Weiss Ratings | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.11 | |||
| Price History | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.52% | |||
| 30-Day Total Return | -10.35% | |||
| 60-Day Total Return | -20.76% | |||
| 90-Day Total Return | -11.30% | |||
| Year to Date Total Return | -10.08% | |||
| 1-Year Total Return | -50.08% | |||
| 2-Year Total Return | -42.61% | |||
| 3-Year Total Return | -57.91% | |||
| 5-Year Total Return | -47.10% | |||
| 52-Week High % Change | -51.54% | |||
| 52-Week Low % Change | 4.71% | |||
| Price | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $35.80 | |||
| 52-Week Low Price | $16.57 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 07, 2024 | |||
| Valuation | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.19B | |||
| Enterprise Value | 2.51B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.16 | |||
| Earnings Per Share Growth | 85.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 867.50 | |||
| Price/Book (Q) | 41.43 | |||
| Enterprise Value/Revenue (TTM) | 1,005.00 | |||
| Price | $17.67 | |||
| Enterprise Value/EBITDA (TTM) | -4.14 | |||
| Enterprise Value/EBIT | -4.01 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 124.85M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 626 304 3400 | |||
| Address | 177 East Colorado Boulevard Pasadena, CA 91105 | |||
| Website | arrowheadpharma.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -25,037.88% | |||
| Profit Margin | -25,588.56% | |||
| Management Effectiveness | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -47.71% | |||
| Return on Equity | -- | |||
| Income Statement | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.50M | |||
| Total Revenue (TTM) | 2.50M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 2.50M | |||
| EBITDA (TTM) | -606.38M | |||
| EBIT (TTM) | -625.95M | |||
| Net Income (TTM) | -639.71M | |||
| Net Income Avl. to Common (TTM) | -639.71M | |||
| Total Revenue Growth (Q YOY) | -29.60% | |||
| Earnings Growth (Q YOY) | -29.43% | |||
| EPS Diluted (TTM) | -5.16 | |||
| EPS Diluted Growth (Q YOY) | -12.10% | |||
| Balance Sheet | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 550.84M | |||
| Cash Per Share (Q) | $4.41 | |||
| Total Current Assets (Q) | 570.54M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 56.08M | |||
| Current Ratio (Q) | 6.085 | |||
| Book Value Per Share (Q) | $0.42 | |||
| Total Assets (Q) | 1.01B | |||
| Total Current Liabilities (Q) | 93.76M | |||
| Total Debt (Q) | 872.05M | |||
| Total Liabilities (Q) | 957.62M | |||
| Total Common Equity (Q) | 52.59M | |||
| Cash Flow | ARWR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -408.00M | |||
| Cash from Financing (TTM) | 890.89M | |||
| Net Change in Cash (TTM) | -4.33M | |||
| Levered Free Cash Flow (TTM) | -382.80M | |||
| Cash from Operations (TTM) | -491.28M | |||
